Tuesday, December 2, 2014
Telik, a clinical stage oncology drug development company based in California, which recently merged with MabVax Therapeutics in July, has appointed six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger.
Avanir Pharmaceuticals, a biopharmaceutical company focused on central nervous system disorders, has announced that the FDA has accepted the company’s New Drug Application (NDA) of AVP-825, its innovative Breath Powered investigational drug-device combination product for the acute treatment of migraine.
Avanir Pharmaceuticals, a biopharmaceutical company focused on central nervous system disorders of high unmet medical need, has submitted a NDA to the FDA for approval of AVP-825, its innovative Breath Powered investigational drug-device combination product for the acute treatment of migraine.
Pharmaceutical company BioDelivery Sciences International (BDSI), headquartered in Raleigh, N.C., has hired Adrian Hepner, M.D., Ph.D., as vice president of clinical research and regulatory affairs. Hepner joins BDSI with over 20 years of experience in U.S. and international clinical research and drug development, including development and implementation of the clinical and regulatory strategy for a number of products from early stage development through NDA and E.U. regulatory filings.
Avanir Pharmaceuticals and OptiNose have entered into an exclusive North American license agreement for the development and commercialization of OptiNose’s novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first dry-powder nasal delivery form of sumatriptan.